In the bleomycin model of pulmonary fibrosis, treatment with the DDX3 inhibitor RK-33 potentiated survival, attenuated inflammation and fibrosis, and reduced lung tissue levels of DDX3, TGF-β1, and NEU3 in young male mice. This evidence concerns the gene TGFB1 and pulmonary fibrosis.